» Articles » PMID: 16619045

Expression of HTERT Immortalises Normal Human Urothelial Cells Without Inactivation of the P16/Rb Pathway

Overview
Journal Oncogene
Date 2006 Apr 19
PMID 16619045
Citations 59
Authors
Affiliations
Soon will be listed here.
Abstract

The CDKN2A locus is frequently inactivated in urothelial cell carcinoma (UCC), yet how this alteration contributes to bladder tumorigenesis is not known. Although most UCC express telomerase, inactivation of the p16/Rb pathway is generally required for in vitro immortalisation. This and the involvement of p16 in senescence of normal human urothelial cells (NHUC) suggest that CDKN2A deletion may aid bypass of senescence and allow immortalisation. CDKN2A encodes p16 and p14ARF and therefore inactivation of this locus can disrupt both the Rb and p53 tumour suppressor pathways. Retrovirus-mediated transduction was used to specifically modulate the p16/Rb and/or p53 tumour suppressor pathways in NHUC and to express human telomerase reverse transcriptase (hTERT). Expression of hTERT bypassed Rb and p53 pathway-dependent barriers to proliferation and immortalised NHUC. TERT-NHUC had normal karyotypes, were non-tumorigenic and unexpectedly retained CDKN2A. Thus, the phenotypic significance of inactivation of CDKN2A in UCC may not be solely related to bypass of senescence. Phenotypic assays in human urothelial cells have relied on cell strains derived from invasive tumours or NHUC immortalised by expression of SV40-large T. The production of genetically normal but immortal NHUC lines now provides a valuable platform for experiments to examine the timing and combination of events necessary for UCC tumorigenesis.

Citing Articles

Tissue factor signalling modifies the expression and regulation of G1/S checkpoint regulators: Implications during injury and prolonged inflammation.

Featherby S, Faulkner E, Ettelaie C Mol Med Rep. 2024; 31(2).

PMID: 39611476 PMC: 11626423. DOI: 10.3892/mmr.2024.13404.


Loss of LPAR6 and CAB39L dysregulates the basal-to-luminal urothelial differentiation program, contributing to bladder carcinogenesis.

Lee S, Bondaruk J, Wang Y, Chen H, Lee J, Majewski T Cell Rep. 2024; 43(5):114146.

PMID: 38676926 PMC: 11265536. DOI: 10.1016/j.celrep.2024.114146.


promoter mutations and methylation for telomerase activation in urothelial carcinomas: New mechanistic insights and clinical significance.

Liu T, Li S, Xia C, Xu D Front Immunol. 2023; 13:1071390.

PMID: 36713366 PMC: 9877314. DOI: 10.3389/fimmu.2022.1071390.


The urothelium: a multi-faceted barrier against a harsh environment.

Jafari N, Rohn J Mucosal Immunol. 2022; 15(6):1127-1142.

PMID: 36180582 PMC: 9705259. DOI: 10.1038/s41385-022-00565-0.


The effect of antibiotics and photodynamic therapy on extended-spectrum beta-lactamase (ESBL) positive of in urothelial cells.

Al-Sarraj F Saudi J Biol Sci. 2021; 28(10):5561-5567.

PMID: 34588866 PMC: 8459124. DOI: 10.1016/j.sjbs.2021.05.074.